UK NICE To Pharma Firms: Up Your Game In Horizon Scanning
Executive Summary
Pharmaceutical companies must play a fuller part in planning for health technology appraisals by NICE, which has resource limitations and cannot do everything that companies might expect of it, a recent workshop in London heard.
You may also be interested in...
UK’s NICE Price Discounts ‘Pass Risk To Patients’
Health technology appraisal mechanisms like discounts do nothing to address a lack of clinical evidence and simply transfer the uncertainty to patients, NICE’s recent annual conference heard.
ABPI Exec Lauds Innovation And Access Provisions In New UK Voluntary Scheme
Speakers at a meeting in London examined the key provisions of the new voluntary pricing and access scheme, which replaced the PPRS at the beginning of January. The Pink Sheet spoke to the Association of the British Pharmaceutical Industry’s Paul Catchpole about enhanced planning for the introduction of new treatments on the national health service, and the shape of the new “commercial flexibilities” intended to allow earlier patient access to innovation.
UK NICE Review Will Look At Criteria For Appraising Highly Specialized Products
The UK's HTA body, NICE, says a more scientific criteria should be used to decide how many products should be admitted to its program for evaluating highly specialized technologies.